Comparative study of Avelumab (anti-PD-L1 antibody) and chemotherapy in the treatment of gastric cancer/gastroesophageal junction cancer showed that the clinical activity of avelumab is not superior to chemotherapy, but avelumab is safer than chemotherapy (Bang et al., 2018). The gene discussed is CD274; the disease is gastric cancer.